Metropolitan Life Insurance Co. NY increased its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 25.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 13,303 shares of the biotechnology company’s stock after purchasing an additional 2,715 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Atara Biotherapeutics were worth $489,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ATRA. SG Americas Securities LLC purchased a new position in Atara Biotherapeutics in the first quarter worth approximately $107,000. Great West Life Assurance Co. Can grew its position in Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 1,655 shares during the period. Bank of Montreal Can purchased a new position in Atara Biotherapeutics in the second quarter worth approximately $180,000. Highland Private Wealth Management purchased a new position in Atara Biotherapeutics in the second quarter worth approximately $202,000. Finally, Principal Financial Group Inc. purchased a new position in Atara Biotherapeutics in the first quarter worth approximately $214,000.

In other news, CEO Isaac E. Ciechanover sold 58,400 shares of the firm’s stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $2,336,000.00. Following the completion of the transaction, the chief executive officer now directly owns 812,613 shares in the company, valued at $32,504,520. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Christopher Haqq sold 31,500 shares of the firm’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $40.17, for a total value of $1,265,355.00. Following the transaction, the executive vice president now owns 317,286 shares of the company’s stock, valued at $12,745,378.62. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 142,675 shares of company stock valued at $5,593,522. Company insiders own 10.60% of the company’s stock.

ATRA has been the subject of several analyst reports. BidaskClub lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. Citigroup lowered their price objective on Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating for the company in a research report on Monday, June 11th. Finally, Jefferies Financial Group restated a “buy” rating and set a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $43.17.

ATRA opened at $40.80 on Friday. Atara Biotherapeutics Inc has a 52 week low of $12.65 and a 52 week high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.17). research analysts anticipate that Atara Biotherapeutics Inc will post -4.58 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Do stock splits help investors?

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.